Wells Fargo analyst Mohit Bansal raised the firm’s price target on Milestone Pharmaceuticals (MIST) to $8 from $4 and keeps an Overweight rating on the shares. The firm says Cardamyst’s robust label, its reasonable pricing and management’s launch strategy bode well for a strong launch. Wells continues to see upside potential to stock despite recent strong performance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals upgraded to Buy at TD Cowen after Cardamyst approval
- Milestone Pharmaceuticals upgraded to Buy from Hold at TD Cowen
- Milestone Pharmaceuticals Poised for Success with Cardamyst Approval and Strong Market Potential
- Milestone Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
- Milestone Pharmaceuticals Gains FDA Approval for CARDAMYST